Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent

Inhaled Corticosteroids in COPD: Trying to Make a Long Story Short

(2020) Claudio Tantucci et al.   International Journal of Chronic Obstructive Pulmonary Disease

Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics

(2019) Mario Cazzola et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation

(2019) Peter MA Calverley et al.   International Journal of Chronic Obstructive Pulmonary Disease

Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis

(2018) Mario Cazzola et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

The effect of erdosteine on airway defence mechanisms and inflammatory cytokines in the settings of allergic inflammation

(2018) S. Fraňová et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study

(2017) Roberto W. Dal Negro et al.   EUROPEAN RESPIRATORY JOURNAL

Protective role of erdosteine pretreatment on oleic acid–induced acute lung injury

(2017) Ayşen Erdem et al.   JOURNAL OF SURGICAL RESEARCH

The role of oxidative stress in influenza virus infection

(2017) Miaomiao Liu et al.   MICROBES AND INFECTION

The Challenges of Precision Medicine in COPD

(2017) Mario Cazzola et al.   Molecular Diagnosis & Therapy

Withdrawal of inhaled corticosteroids in COPD: A meta-analysis

(2017) Luigino Calzetta et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Anti-inflammatory Effect of Erdosteine in Lipopolysaccharide-Stimulated RAW 264.7 Cells

(2016) Jong Sun Park et al.   INFLAMMATION

Erdosteine reduces the exercise-induced oxidative stress in patients with severe COPD: Results of a placebo-controlled trial

(2016) Roberto W. Dal Negro et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives

(2015) Mario Cazzola et al.   DRUGS

Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial

(2015) R.W. Dal Negro et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD

(2015) Ian D Pavord et al.   THORAX

Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD

(2015) Maurizio Moretti et al.   International Journal of Chronic Obstructive Pulmonary Disease

Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases

(2012) I-Ta Lee et al.   BIOCHEMICAL PHARMACOLOGY

Acute Exacerbations of Chronic Obstructive Pulmonary Disease

(2011) Mona Bafadhel et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Erdosteine affects eicosanoid production in COPD

(2011) R.W. Dal Negro et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Free Radical Scavenging Activity of Erdosteine Metabolite I Investigated by Electron Paramagnetic Resonance Spectroscopy

(2010) Pier Carlo Braga et al.   PHARMACOLOGY

The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data

(2009) M. Cazzola et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD

(2008) Roberto Dal Negro et al.   Therapeutic Advances in Respiratory Disease

Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: A controlled study in current smokers with mild COPD

(2007) R.W. Dal Negro et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS